Teva Pharmaceutical Industries Limited : Teva to Report Second Quarter 2012 Financial Results on August 2, 2012
07/13/2012| 12:50pm US/Eastern
Recommend:
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its second quarter 2012 financial results on Thursday,
August 2, 2012 at 7:00 a.m. EDT.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. EDT to discuss its second quarter 2012 results and overall
business environment. A Question & Answer session will follow this
discussion.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States and Canada
1-888-713-4205; International 617-213-4862; passcode: 68430667.
A live webcast of the call will also be available on Teva's website at: www.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software. Participants may preregister
for the call at: https://www.theconferencingservice.com/prereg/key.process?key=PW6YQWDV4
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until August 9, 2012, at 11:59 p.m. ET by calling
1-888-286-8010 or 617-801-6888; passcode: 26396486.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,300 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $18.3 billion
in net revenues in 2011.
Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin
C. Mannix, 215-591-8912
or
PR:
United States
Denise
Bradley, 215-591-8974
or
Israel
Shir Altay-Hagoel,
972-3-926-7590
© Business Wire 2012
Recommend :
